Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Integra Lifesciences Holdings Corp

NASDAQ: IART · Industrial Applications and Services · 5 alerts · CIK 917520

Share price
$13.98Close, Nov 16
Market cap
$1.09B
Shares outstanding
77.8MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Integra Lifesciences Holdings Corp filings on SEC EDGAR ↗

4:01 PM ET 10-Q
Financial Results

Integra Lifesciences Holdings Q3 2026 Results: Turns Profitable, Net Income $14.9M

Integra LifeSciences reported net income of $14.9 million for the third quarter of 2026, a significant recovery from a net loss of $5.4 million in the prior year period. Total revenue grew slightly to $411.2 million, while the company successfully reduced selling, general, and administrative expenses compared to 2025.

Key figure
Net income $14.9M
6:15 AM ET 8-K
Financial Results

Integra Lifesciences Holdings Financial Results

Integra LifeSciences reported Q3 2026 revenues of $411.2 million, a 2.3% increase year-over-year, despite a $7 million impact from flood damage at its Cincinnati facility. The company achieved GAAP net income of $14.9 million ($0.19 per share) and adjusted EPS of $0.59, while generating $96 million in operating cash flow.

Term
Q3 2026

“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”

Stuart Essig, Chairman and Chief Executive Officer

“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”

Stuart Essig, Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.